| 6.79 0.14 (2.11%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.04 | 1-year : | 9.92 |
| Resists | First : | 7.73 | Second : | 8.5 |
| Pivot price | 7.23  |
|||
| Supports | First : | 6.51 | Second : | 5.41 |
| MAs | MA(5) : | 6.81 |
MA(20) : | 7.25 |
| MA(100) : | 6.88 |
MA(250) : | 6.52 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16.5 |
D(3) : | 18.3 |
| RSI | RSI(14): 44.6 |
|||
| 52-week | High : | 8.94 | Low : | 3.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PROF ] has closed above bottom band by 31.2%. Bollinger Bands are 109.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.96 - 6.99 | 6.99 - 7.02 |
| Low: | 6.54 - 6.57 | 6.57 - 6.61 |
| Close: | 6.73 - 6.79 | 6.79 - 6.84 |
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
Fri, 21 Aug 2026
Profound Medical Corp (NASDAQ: PROF) Share Price, PROF Stock News, PROF Share Price & Updates - kalkine.ca
Mon, 17 Aug 2026
Profound Medical (NASDAQ: PROF) targets higher TULSA throughput - Stock Titan
Mon, 17 Aug 2026
Some physicians report four TULSA procedures a day—what changes next? - Stock Titan
Mon, 17 Aug 2026
Profound Medical (PROF) shifts CFO, ex-finance chief stays on as paid adviser - Stock Titan
Fri, 14 Aug 2026
Profound Medical Announces Management Change - Yahoo Finance
Thu, 06 Aug 2026
Profound Medical (NASDAQ: PROF) Q2 loss narrows as revenue rises - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 36 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 4 (%) |
| Held by Institutions | 44.5 (%) |
| Shares Short | 1,850 (K) |
| Shares Short P.Month | 2,140 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.62 |
| Profit Margin | -206.8 % |
| Operating Margin | -150.3 % |
| Return on Assets (ttm) | -35.5 % |
| Return on Equity (ttm) | -70.6 % |
| Qtrly Rev. Growth | 103.5 % |
| Gross Profit (p.s.) | 0.36 |
| Sales Per Share | 0.51 |
| EBITDA (p.s.) | -1.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -6.86 |
| PEG Ratio | 0 |
| Price to Book value | 4.16 |
| Price to Sales | 13.11 |
| Price to Cash Flow | -6.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|